Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.

European review for medical and pharmacological sciences - 1 Jan 2017

Ma X-H, Tian T-D, Liu H-M, Li Q-J, Gao Q-L, Li L, Shi B

Abstract excerpt

OBJECTIVE: To evaluate the efficacy and safety of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and discuss the influence factors on efficacy. PATIENTS AND METHODS: 120 treatment-experienced patients confirmed by pathology or cytology with stage III B-IV non-small cell lung cancer took icotinib hydrochloride and erlotinib orally until the occurrence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Crown Ethers

Share to Disease-Free Survival

Share to Lung Neoplasms

Share to Quinazolines

Source

Identifiers

PMID: 28165562

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.PMID 28165562Read ↗

[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].Semantic proximity Read ↗

[Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].Semantic proximity Read ↗

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Semantic proximity Read ↗

Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Status and progress of Icotinib in treatment of EGFR-mutant non-small cell lung carcinomaSemantic proximity Read ↗

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].Semantic proximity Read ↗

Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.Semantic proximity Read ↗

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.Semantic proximity Read ↗

[The therapeutic value and safety of icotinib as first-line therapy for advanced non-small cell lung cancer patients].Semantic proximity Read ↗

[Clinical Analysis of Icotinib on Beneficiary of Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].Semantic proximity Read ↗

[Expert consensus on icotinib as adjuvant therapy for non-small cell lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.